Clinical Trial

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Study acronym: REMAP-CAP
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 12, 2024 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2016-04-06; most recent amendment 2024-07-10.
Trial Details
NCT Number NCT02735707
Lead Sponsor UMC Utrecht
Collaborators: Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Conditions Community-acquired Pneumonia, Influenza, COVID-19
Enrollment 20,000 participants
Start Date 2016-04-11
Primary Completion 2026-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2024-07-12